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S172 Oral PresentationsAlthough it should be too early to refer long term outcome, unma-
nipulated haploSCT could be considered as an option to fight
against refractory diseases.
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Background: After myeloablative dCBT, one unit typically persists
as the engrafting unit responsible for long-term hematopoiesis. It has
been postulated that unit-versus-unit immune interactions contrib-
ute to the emergence of single donor dominance; however, there is
currently no reliable method of determining the winning unit. We
evaluated the role of donor day 7 CD3 peripheral blood (PB) chime-
risms on predicting the engrafting unit.
Methods: In this prospective single-center analysis, PB was flow
sorted into cell fractions, and DNA chimerism analysis was
performed by amplified fragment length polymorphism. Chimerism
detection sensitivity was 1-5%, with a range of accuracy 1/- 5%. A
logistic regression model was used to determine the correlation be-
tween a higher CD3 chimerism and the likelihood of being the pre-
dominant unit, and a t-test was applied to compare the mean CD3
chimerism of the winning versus losing unit.
Results: Between 10/2007-7/2010, 29 patients aged 12-63 years un-
derwent myeloablative dCBT for AML (n5 14), ALL (n5 8), CML
(n 5 2), MDS/MPD (n 5 4), and CLL (n 5 1). 17 patients received
13.2 Gy TBI, 120 mg/kg cytoxan, and 75 mg/m2 fludarabine; 12 pa-
tients received treosulfan 42 gm/m2, fludarabine 150 mg/m2, and 2
Gy TBI. GVHD prophylaxis was cyclosporine and MMF. The me-Table 1. Patient Characteristics
All Cohort
(n529) N(%)
Group A
(n521) N(%)
Group B
(n54) N(%) p value
Median age in
years (range)
31.6 (12.9-63.3) 33.3 (12.9-63.3) 24.9 (17.7-56.3) 0.76
Gender 0.93
Female 15 (52) 10 (47) 2 (50)
Male 14 (48) 11 (53) 2 (50)
HLA disparity* 0.20
4/6 19 (66) 14 (67) 1 (25)
5/6 8 (27) 6 (29) 2 (50)
6/6 2 (7) 1 (4) 1 (25)
CMV serostatus 0.65
Positive 18 (62) 13 (62) 2 (50)
Negative 11 (38) 8 (38) 2 (50)
Transplant type 0.50
Flu+Cy+TBI (13.2 Gy) 17 (81) 12 (57) 3 (75)
Flu+Treosulfan 12 (19) 9 (43) 1 (25)
GVHD prophylaxis CSA+MMF - - -
Median weight
in Kg (range)
76.1 (45.5-114.4) 76.1 (47.7-114.4) 72.2 (66-78.4) 0.57
Disease 0.96
AML 14 (48) 11 (52) 2 (50)
ALL 8 (28) 5 (24) 1 (25)
CML 2 (7) 1 (5) -
MDS/MPD 4 (14) 3 (14) 1 (25)
CLL 1 (3) 1 (5) -
Median TNC infused**
x107/Kg (range)
3.5 (1.8-6.4) 3.3 (2.3-6.4) 3.3 (2.6-4.0) 0.61
Median CD34 infused**
x106/Kg (range)
0.16 (0.08-0.66) 0.14 (0.08-0.66) 0.26 (0.20-0.31) 0.23
Median CD3 infused***
x106/Kg (range)
10.7 (6.9-18.5) 10.8 (6.9-18.5) 10.4 (9.4-16.4) 0.92
Viability*** % (range) 75 (60-87) 74 (60-87) 78 (72-79) 0.33
*For dCBT, HLA disparity reflects the lower match of the 2 units.
**Post thaw.
***Post wash.dian infused cell doses were: 3.5  107 TNC/kg, 0.16  106 CD34/
kg, and 10.7  106 CD3/kg. Day 7 CD3 chimerisms were evaluable
in 25/29 patients. We found no correlation between engrafting unit
and infused TNC, CD34, or CD3 dose, nor unit viability or HLA
disparity. In 21/25 patients (Group A), the unit with higher CD3 chi-
merism on day 7 became the engrafting unit [OR 27.5 (95%CI: 6.0-
125.0), p 5 0.0001]. Furthermore, the mean day 7 CD3 chimerism
was significantly different between the winning and losing units in
this group (p\ 0.0001). CD3 chimerism from the non-engrafting
unit was higher at day 7 in only 4 patients (Group B).
Conclusions: Donor day 7 CD3 peripheral blood chimerism is
highly predictive of the long-term engrafting unit in the setting of
myeloablative dCBT. These results further support the hypothesis
that single-donor dominance is immune-mediated by graft-graft in-
teractions, andmay provide insight into basic principles of transplant
immunology. Importantly, the ability to predict the long-term en-
grafting unit at day 7 would allow for early selection of the cord
blood unit to be used for adoptive immunotherapy post transplant.55
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High resolution HLA matching at HLA-A, B, C and DRB1 has
proven critical for optimal outcomes following unrelated donor
(URD) hematopoietic stem cell transplantation (HCT). Approxi-
mately 30% of URD HCT facilitated through by the National Mar-
row Donor Program (NMDP) are mismatched (MM) at one or more
loci. Currently, no rating system exists to reliably predict which HLA
MM URD should be selected for patients who do not have an HLA
allele matched donor. In 2002, Elsner and Blasczyk suggested that
a rating system, HistoCheck, might be used to identify acceptable
MM. This algorithm is based on the functional similarity of amino
acids weighted based on the position of the disparity in the HLAmol-
ecule to yield a Dissimilarity Score (DSS).
We evaluated the ability of DSS to predict the risk associated with
HLA disparity in a population of 744 single allele or antigen HLA-
A, B, or C MM myeloablative URD HCT for AML, ALL, CML or
MDS facilitated through the NMDP from 1988-2003. All pairs in
the study were retrospectively high resolution typed for HLA-A, B,
C, DRB1, DQB1 and DPB1. Multivariate models were used to adjust
for other significant clinical risk factors. A threshold of p\ 0.01 was
used to define significance due to multiple comparisons. HLA MM
were scored using the HistoCheck web-based tool and the patients
divided into 4 quartiles: DSS 1.04-2.84 (alleleMM), 2.84-13.75 (allele
and antigen MM), 13.75-19.385 (antigen MM) and 10.385-36.62
(antigen MM). Using the lowest scoring quartile as the reference, the
DSS groups were evaluated for an association with relapse, transplant
related mortality (TRM), acute and chronic GVHD, leukemia free
survival (LFS), and overall survival in the entire cohort and in subset
analyses by disease and disease stage.
No significant associations were found between DSS and any out-
comes in the overall cohort using the quartile categories or treating
DSS as a continuous variable. Higher DSS scores were associated with
decreased engraftment in early stage disease (p 5 0.0003) but not in
other disease stages. In disease subset analyses,DSS scorewas associated
with TRM, LFS and OS inMDS. However, theMDS subgroups were
very small (n5 10-21) diminishing confidence in the association.
In summary, DSS does not correlate with transplant outcome, and
theHistoCheck scoring system does not provide an effective strategy
to rank HLAMM. The dataset used in this study is available to eval-
uate new algorithms developed for donor selection.
